Chardan: After Dicerna Pharma's 370% Run, Wait For Better Entry Point

By: via Benzinga
Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) could become a player in the emerging field of small RNA interference, or RNAi, according to ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.